ENTITY
BeiGene

BeiGene (6160 HK)

438
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
bullishBeiGene
17 Feb 2025 12:21

Quiddity Leaderboard Hang Seng Index: Healthcare Is Still the Most Under-Represented Industry Group

The Hang Seng Index February 2025 index review results will be confirmed on Friday this week (21st). This would be a good time to revisit this...

Share
bullishBeiGene
17 Dec 2024 10:21

HK CEO & Director Dealings (17th Dec 2024): BeiGene, China Wantian, Super Hi Int'l/Haidilao

The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.  These insights also flag those companies where...

Logo
369 Views
Share
17 Mar 2025 07:30

China & HK Strategy: Who Are the Victims of a US Recession?

​Reliance on the US market varies among HK-listed companies, with some having high direct exposure to a recession. Those with low direct exposure...

Logo
489 Views
Share
bearishXiaomi
21 Feb 2025 05:49

Hang Seng Indexes: Announcement Today; Updated Flows (Some Big Ones)

Hang Seng Indexes announces post market close today. There will be changes for the HSI, HSCEI, HSTECH, HSIII and HSCI indices. The net round-trip...

Logo
2.1k Views
Share
x